# Litigation, liability and off-label risk on the balance sheet
In September 2019, Johnson & Johnson took a $4 billion charge tied to talc litigation in a single quarter, and its stock barely blinked. Investors had already priced in years of jury verdicts, appeals and settlement chatter. That's the strange thing about pharma litigation: it's often huge, predictable in shape, and still hard to read from the outside. This lesson teaches you how to spot it in the numbers.
Drug and device makers face lawsuits over side effects, marketing practices and product defects almost continuously. This isn't a tail risk. It's a recurring cost of doing business in a sector where products are ingested, injected or implanted in millions of bodies.
Three real cases show the range:
These aren't rounding errors. They shape reported earnings, cash flow and even how you should read a "clean" balance sheet.
Two concepts do the heavy lifting.
Litigation reserve: money a company sets aside on its balance sheet because it expects to pay out on a legal claim. Under US GAAP (Generally Accepted Accounting Principles), a company must book a reserve when a loss is *probable* and the amount is *reasonably estimable* (this is the standard under ASC 450). Under IFRS (International Financial Reporting Standards, used across Europe), the equivalent rule is IAS 37, which uses a similar "probable outflow, reliable estimate" test.
Contingent liability: a potential obligation that depends on a future event, like a court ruling. If a loss is only "reasonably possible" rather than probable, companies don't book a reserve. They disclose it in footnotes instead, often in vague language ("we believe we have meritorious defenses").
This creates a real gap between disclosed risk and recognized risk. A company can face $10 billion in claims and report a reserve of $500 million, because management genuinely believes (or argues) only a fraction is probable.
Worked example: Say a pharma company faces 10,000 lawsuits. Legal counsel estimates a 40% chance of losing each case on average, with an average payout of $150,000 per case if lost.
Expected liability = 10,000 × 0.40 × $150,000 = $600 million.
If management judges this "probable and estimable," they book a $600 million reserve, reducing net income by that amount in the period recorded. If instead they judge the outcome too uncertain to estimate reliably, they disclose it as a contingent liability in footnotes with no earnings hit, until a settlement or verdict forces recognition.
That single judgment call, probable versus reasonably possible, can swing reported earnings by hundreds of millions of dollars with no change in the underlying legal exposure.
Reserves are accounting entries; cash payments are what actually move free cash flowfree cash flowFree Cash Flow is the cash a company generates from operations after funding the capital expenditures needed to maintain and grow its asset base.View full definition → (FCFFCFFree Cash Flow is the cash a company generates from operations after funding the capital expenditures needed to maintain and grow its asset base.View full definition →: operating cash flow minus capital expenditures).
Watch for the lag. A company might book a $2 billion reserve in Q1 but pay it out over five years as part of a structured settlement. That means:
Purdue Pharma's opioid settlement, structured through Chapter 11 bankruptcy, involved payments stretched over roughly a decade, into a trust for claimants. This is common: settlements get structured as annuities, not lump sums, partly to manage the paying company's cash flow.
Due diligence check: when analyzing a pharma company, always reconcile the reserve booked in a given year against the actual cash paid in that year (found in the cash flow statement or 10-KKThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.View full definition →/20-F footnotes). A growing gap between the two tells you whether litigation costs are front-loaded or still coming.
Product liability insurance is supposed to cushion these blows, but coverage has real limits in pharma:
This is why large pharma companies self-insure a meaningful chunk of this risk through reserves rather than relying purely on external insurers. When you see "insurance recoveries" as a line item in a 10-KKThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.View full definition →, check whether it's realized cash or merely an assumed future recovery still being contested.
Knowledge check
1. Why did J&J's stock barely react to a multi-billion dollar litigation charge in a single quarter?
2. A pharmaceutical company's drug is being prescribed by doctors for a use not approved by regulators. Under what circumstance does this create legal risk for the company itself, rather than just being a normal part of medical practice?
3. What does the sheer scale and recurrence of litigation across major drug and device makers suggest about how analysts should treat these costs?
4. Select ALL correct answers about why pharma litigation can be 'huge, predictable in shape, and still hard to read from the outside.'
Select all the correct answers.
5. Select ALL correct answers about the distinction between prescribing and promoting a drug off-label.
Select all the correct answers.
To read litigation risk fluently, know the institutional landscape:
Europe generally sees fewer mass-tort-style payouts than the US, partly because of different civil procedure rules (no equivalent to US-style punitive damages or contingency-fee class actions in most EU jurisdictions), and partly because of stricter caps in some national tort systems. This is a genuine structural reason US-listed pharma companies carry higher headline litigation exposure than European peers, not just a reporting artifact.
For primary source detail on how these reserves get disclosed, the SEC's EDGAR database lets you read the actual footnote language companies use in 10-K filings, useful for comparing how conservatively different companies word similar risks.
🎬 [VIDEO: "Johnson & Johnson's Talc Bankruptcy Strategy Explained" - https://www.youtube.com/results?search_query=johnson+and+johnson+talc+bankruptcy+explained - search for recent explainer coverage of the "Texas Two-Step" bankruptcy tactic and how courts have responded to it]
When assessing a pharma company's litigation exposure:
1. Read the contingency footnote in the 10-KKThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.View full definition → (US) or annual report (Europe) line by line; compare language year over year for softening or hardening tone.
2. Track the reserve-to-cash-paid ratio over 3-5 years to spot front-loading or deferral.
3. Check insurance coverage limits against total claim estimates disclosed by plaintiffs' attorneys or court filings.
4. Watch for bankruptcy subsidiary structures (a red flag for aggressive liability isolation, and a source of years-long uncertainty for creditors and investors alike).
5. Compare US versus ex-US exposure: a company with concentrated US sales carries structurally higher mass-tort risk than one diversified into Europe and Asia.